Market news

Haemonetics (HAE) has been drawing investor attention after a strong total return over the past year, along with double-digit annual growth in both revenue and net income. Despite a small dip in the latest session, Haemonetics’ share price is US$108.52, with a strong 90 day share price return of 48.92% and a 1 year total shareholder return of 114.25%. This points to momentum building as investors reassess growth prospects and risk. Scan Haemonetics’ momentum against peers and uncover other...

Haemonetics (HAE) shares were up over 2% in Thursday trading after Citigroup upgraded the stock to b

Haemonetics (HAE) has an average rating of overweight and mean price target of $108.40, according to

Orchestra BioMed (OBIO) said Tuesday it has received $6.1 million as a milestone payment in connecti

Detailed price information for Airbnb Inc Cl A (ABNB-Q) from The Globe and Mail including charting and trades.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Haemonetics (NYSE:HAE) and its peers.

Haemonetics (HAE) has an average rating of overweight and mean price target of $101.80, according to

Haemonetics (HAE) stock jumps as the company reaches a supply agreement with Australian biopharma company CSL Limited (CSLLY) (CMXHF). Read more here.

Haemonetics (HAE) shares were up more than 17% in afternoon trading on Tuesday after the company sai

Haemonetics stock has delivered a strong 69.0% return over the past year, yet the valuation signals are mixed, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) model suggesting the shares trade at a discount, while traditional market multiples lean the other way. Haemonetics has returned 69.0% over the past year, which puts more focus on whether the recent share price strength is backed by fundamentals. Expectations for continued revenue growth from its plasma and...

Haemonetics (HAE) has drawn fresh attention after reporting first quarter fiscal 2027 results, with sales of US$339.38 million and net income of US$33.01 million, alongside a US$391.25 million shelf registration tied to an ESOP related stock offering. See our latest analysis for Haemonetics. Haemonetics’ recent earnings beat, higher revenue guidance and fresh clinical data around VASCADE MVP XL have coincided with a strong 90 day share price return of 61.31%. The 1 year total shareholder...

Haemonetics delivered a Q2 performance that surpassed Wall Street’s revenue and adjusted earnings expectations, supported by consistent execution across its business lines. Management attributed the quarter’s results to strong innovation and commercial momentum, particularly in Plasma and Interventional Technologies, where new product rollouts like Persona PLUS and VASCADE MVP XL drove adoption and utilization. CEO Christopher Simon specifically highlighted, "All three of our core platforms cont

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Haemonetics Corp (HAE-N) from The Globe and Mail including charting and trades.

Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.

Motley Fool Press Release.

Detailed price information for Haemonetics Corp (HAE-N) from The Globe and Mail including charting and trades.

Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Detailed price information for Haemonetics Corp (HAE-N) from The Globe and Mail including charting and trades.

Haemonetics (HAE) delivered earnings and revenue surprises of +6.54% and +3.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) reported fiscal Q1 adjusted earnings Thursday of $1.14 per diluted share, up from

Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 5.6% year on year to $339.4 million. Its non-GAAP profit of $1.14 per share was 5.8% above analysts’ consensus estimates.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Haemonetics Corp (HAE-N) from The Globe and Mail including charting and trades.

Haemonetics recently reported results from a large Emory University retrospective study of 1,623 patients, showing its VASCADE MVP XL venous vascular closure system delivered rapid hemostasis, high same-day discharge rates and low complication rates in large-bore sheath electrophysiology procedures. This new real-world evidence, coming after the FDA’s March 2026 expanded labeling for VASCADE MVP XL up to 17F outer diameter sheaths, strengthens the product’s clinical and procedural...

Detailed price information for Haemonetics Corp (HAE-N) from The Globe and Mail including charting and trades.

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.